All Pharma News
Aravive, Inc. to Delist from The Nasdaq Stock Market

Aravive, Inc. to Delist from The Nasdaq Stock Market
GLOBENEWSWIRE
17 Jan 2024
Share Share
Aravive, weeks from liquidation, lays off 70% of its staff

Aravive, weeks from liquidation, lays off 70% of its staff
Nick Paul Taylor FIERCE BIOTECH
22 Aug 2023
Share Share
Phase 3 cancer flop blows hole in plans of cast-strapped Aravive

Phase 3 cancer flop blows hole in plans of cast-strapped Aravive
Nick Paul Taylor FIERCE BIOTECH
03 Aug 2023
Share Share
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept

Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept
GLOBENEWSWIRE
02 Aug 2023
Share Share
Aravive to Present Updated Clinical Data from Batiraxcept Trials

Aravive to Present Updated Clinical Data from Batiraxcept Trials
GLOBENEWSWIRE
28 Jul 2023
Share Share
Aravive to Participate in William Blair`s Innovator Series

Aravive to Participate in William Blair`s Innovator Series
GLOBENEWSWIRE
14 Jul 2023
Share Share
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)

Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
GLOBENEWSWIRE
13 Jun 2023
Share Share
Aravive To Participate in the Jefferies Global Healthcare Conference

Aravive To Participate in the Jefferies Global Healthcare Conference
GLOBENEWSWIRE
05 Jun 2023
Share Share
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcep

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcep
GLOBENEWSWIRE
25 May 2023
Share Share
Aravive Announces Ph3 Trial Design for Batiraxcept in Renal Cell Carcinoma

Aravive Announces Ph3 Trial Design for Batiraxcept in Renal Cell Carcinoma
GLOBENEWSWIRE
16 May 2023
Share Share